DSIP Peptide for Sleep: What a Psychiatrist Makes of Delta Sleep-Inducing Peptide

DSIP peptide arrives with a name that sounds like a promise: delta sleep-inducing peptide. Unlike a lot of what gets sold online, it has an actual human research record behind it, one that goes back to the 1970s and includes small trials in people with insomnia.

That record is more interesting than either its marketers or its critics let on. At least eight small human studies have tested DSIP for sleep, and most of them reported people sleeping better. The catch is that almost all the positive work comes from the one group that discovered it, the two independent trials were small and came up weak, and every study used an intravenous drip in a lab, while the subcutaneous shot sold today has never been tested.

I don’t offer DSIP, and I want to be clear about why up front. It isn’t FDA-approved, it’s sold as a “research chemical,” and the route people actually inject has never been studied in a human being. But it’s a fair question with a real, if thin, evidence base, so here’s the clinical read on the DSIP peptide: what it is, what the studies show, and where the uncertainty sits.

What the DSIP Peptide Actually Is

DSIP is a synthetic nonapeptide, a chain of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Two researchers in Basel, Marcel Monnier and Guido Schoenenberger, first pulled it from the cerebral venous blood of rabbits whose sleep had been induced by electrical stimulation, and they sequenced and synthesized it in the late 1970s (1).

The molecule itself is well described. Where it gets murky is the biology. Decades after the discovery, a 2006 review still called DSIP “a still unresolved riddle” and noted that no DSIP gene, no precursor protein, and no receptor had ever been found (2). Its natural role in the body isn’t settled, and plasma levels don’t track sleep the tidy way the name implies. The molecule is well-characterized; its job in the body isn’t. The marketing mentions the first part and skips the second.

Does DSIP Actually Work for Sleep?

The human record on sleep is thin, and most of it leans positive. Since 1981, at least eight studies have tested DSIP in people for sleep. Most reported the same pattern: people slept longer and more efficiently, felt more alert the next day, and didn’t get the grogginess or hangover you’d expect from a sedative. In healthy volunteers, one study measured a 59% increase in sleep versus placebo (3). In chronic insomniacs, a double-blind, placebo-controlled study found both nighttime sleep and next-day performance improved significantly (4). One open study reported the benefit holding for three to seven months after treatment (5).

Almost all of that positive work, though, traces back to the same Basel research network that discovered DSIP (6). The only two fully independent teams that tested it, in Montevideo and Amsterdam, got weak or null results (7, 8). And those two independent trials were tiny, about six and eight patients per group, which is too small to settle the question either way. Every one of these studies, positive and negative, used an intravenous infusion in a sleep lab. None used the subcutaneous injection sold today.

The fair verdict is that DSIP was never properly tested for sleep. No adequately powered, independent, randomized trial has ever been run. That leaves a signal worth taking seriously and still a long way from proof.

How DSIP Is Supposed to Work

The best-studied action is electrical. Given DSIP directly into the brain ventricles of an animal, delta and spindle EEG activity goes up, with delta power rising about 35% in parts of the cortex (1). That effect is where the name comes from, and it’s well documented in animals. Whether it survives the trip from a rabbit’s brain to a person’s subcutaneous tissue is a separate question, and the human mechanism is still fuzzy given that no receptor or gene has been identified (2).

Two mechanism claims in the marketing are worth correcting. DSIP is often sold as an opioid-receptor agonist for withdrawal. The direct test found it doesn’t bind opioid receptors at all, but it can trigger release of the body’s own enkephalins, which is a different and indirect route to a similar place (9). And the “lowers cortisol, resets your HPA axis” line rests on mixed human data: one small controlled study found DSIP reduced ACTH, another found no effect on ACTH or cortisol at all (10, 11). In humans, the stress-hormone story isn’t established in either direction. If stress physiology and disrupted sleep are the underlying problem, that’s a legitimate clinical target, and I write about the hormone side of it in my piece on how hormones and mental health interact.

DSIP vs Melatonin vs Epitalon

Patients usually ask about DSIP alongside the other “sleep peptides,” so here’s how it lines up against melatonin, the only one of these with regulatory standing in the US, and against epitalon, the pineal-support peptide it often gets grouped with.

Feature	DSIP	Melatonin	Epitalon
What it is	Synthetic 9-amino-acid peptide	Endogenous hormone your pineal gland makes	Synthetic 4-amino-acid peptide
Proposed mechanism	Delta/slow-wave EEG activity (shown in animals)	Binds MT1/MT2 receptors, signals circadian timing	Supports pineal melatonin output
Human sleep evidence	~8 small studies, mostly positive but largely from one group; no powered independent RCT	Modest, strongest for shifting sleep timing	Limited, preliminary
US status	Not FDA-approved; research chemical; under FDA compounding review	Sold over the counter as a dietary supplement	Not FDA-approved; also under FDA compounding review
Identified receptor	None	Yes (MT1, MT2)	None specific

Melatonin is the reference point because it’s a hormone your body actually makes, with an identified receptor and a modest but replicated evidence base. DSIP sits in a different spot: a bigger and more encouraging pile of small human sleep studies than most people realize, but without the independent, adequately powered trial that would turn a signal into a fact. It’s interesting, and not yet settled.

The Other Claims DSIP Is Marketed For

Sleep is the strongest part of the DSIP story. The second strongest is withdrawal, and it’s better than I expected. Two independent groups, one in Geneva and one in Munich, reported that DSIP eased opioid and alcohol withdrawal in a series of open-label studies, with most patients improving (12, 13). That independent replication matters, because it moves the finding past a single lab. The honest limit is that all of it is open-label, with no control group and no randomized trial in more than 40 years. It’s a promising signal that nobody has confirmed properly.

Past sleep and withdrawal, the evidence thins out fast. For pain, there’s a single small open-label pilot in which 6 of 7 patients improved (14). For depression, there’s no treatment trial at all, only observations that DSIP levels shift in depressed patients, which is a different thing from DSIP treating depression. For “anti-aging,” antioxidant, and geroprotective claims, the data are entirely from rodents, with nothing in humans. When a product is marketed for that many conditions and only two of them have even preliminary human signals, the marketing is running well ahead of the evidence. I apply the same reasoning to any peptide pitched against a proven drug, which I walk through in peptides versus SSRIs for depression and anxiety.

Safety and the Research-Chemical Problem

The old human studies described DSIP as well tolerated, with no next-day hangover or sedation (3, 6). That’s reassuring as far as it goes, but it doesn’t go far. Those were small studies, the largest under 20 people, all from the 1980s and 1990s, and all intravenous. There’s no modern pharmacovigilance, no long-term follow-up, and no immunogenicity data for repeated use.

There’s also a route-and-dose problem that even the pro-DSIP case has to reckon with. Every human study infused DSIP intravenously at roughly 25 nmol/kg, about 1.5 mg for an adult. The protocol sold to consumers is a fixed subcutaneous shot of around 100 micrograms, which is a different route at something like a tenth to a fifteenth of the studied dose. The encouraging studies used a delivery method and a dose that almost nobody buying DSIP online is actually using. The subcutaneous route has never been tested in a human at all.

Then there’s the product. DSIP reaching consumers is unapproved “research chemical” or compounded peptide, well short of the pharmaceutical-grade material you’d want for anything injected. In its briefing document for the July 2026 meeting, the FDA called emideltide (the name DSIP goes by in that review) “not well-characterized,” flagged missing data on impurities, aggregates, and endotoxins, and raised specific concern about immunogenicity for an injectable peptide given under the skin (15). No one has shown DSIP to be dangerous. But injecting a peptide of uncertain purity by an untested route makes you the experiment.

Is DSIP FDA-Approved?

No. DSIP is not FDA-approved for any use, and it isn’t a dietary supplement either. As a synthetic peptide drug it falls outside the supplement definition, which is why it’s sold as a research chemical labeled not for human consumption.

As of July 2026, it’s under active federal review. The FDA’s Pharmacy Compounding Advisory Committee is meeting on July 23 and 24, 2026, to weigh seven peptides for the 503A bulk drug substances list, the ingredients compounding pharmacies are allowed to use (16). DSIP appears on the agenda as “emideltide,” scheduled for the second day (16). Ahead of the meeting, the FDA’s own reviewers recommended against adding it, pointing to the small, mostly non-independent studies and the characterization and safety gaps above, and calling the sleep evidence “inconclusive and at best preliminary” (15).

Two things are worth understanding about how this works. First, the advisory committee votes separately from the staff, and it isn’t bound by the staff’s recommendation. A committee can, and sometimes does, vote to add a substance its reviewers opposed. Second, even a favorable vote is only a recommendation. It would make DSIP eligible for pharmacy compounding, and the FDA would still have to accept that recommendation and complete formal rulemaking, a process that runs a year or more. I’ll update this section once the committee’s DSIP vote is confirmed to a primary source. For the wider picture, I broke down the whole peptide review in my guide to the 2026 FDA peptide decision.

If sleep or stress has become a serious problem for you, that’s worth an actual evaluation with someone who treats it. Book a consultation and we can talk through the options that do have evidence behind them, including the ones I cover in my psychiatrist’s guide to sleep medications and peptides.

DSIP and Psychiatric Medications

Patients on an SSRI, a stimulant, or a mood stabilizer often ask whether it’s safe to add a peptide like DSIP. There’s no direct data to answer that, because there are no human studies of DSIP combined with any psychiatric medication. Its possible effects on the stress axis and on the body’s own enkephalins are exactly the kind of overlap that would matter if they were better characterized in people, and they aren’t yet.

The principle I use for any peptide alongside psychiatric care applies here, and I lay it out in my guide to peptides with psychiatric medications: nothing gets added to a regimen without the prescribing clinician’s awareness, and an uncharacterized interaction is a reason to go slow. If you’re on psychiatric medication and considering DSIP, the move is to bring it to the clinician who manages that medication, instead of running it in parallel and hoping.

Why This Article Gives No Dosing Protocol

You’ll notice I haven’t laid out a dose, a schedule, or an injection technique, and that’s deliberate. The only doses ever studied in people were intravenous, in a lab, decades ago. The subcutaneous protocol sold online has never been tested in a human, DSIP isn’t FDA-approved, and it’s under active FDA review as of July 2026. Publishing a how-to for an untested route of an unapproved drug would imply a confidence the evidence hasn’t earned, and it would read as instruction to use something I don’t offer and wouldn’t prescribe. Explaining what the research shows is one thing. Handing someone a protocol is another, and only the first belongs in a public article.

Frequently Asked Questions

Does DSIP actually work for sleep?

The human evidence leans positive but is far from settled. At least eight small studies since 1981 mostly reported better sleep and next-day alertness without sedation, but nearly all the positive work came from the group that discovered DSIP, the two independent trials were small and weak, and every study used intravenous dosing, while the subcutaneous route sold today has never been tested. The fair reading is that DSIP is under-tested, which isn’t the same as proven or disproven.

Is DSIP FDA-approved?

No. DSIP is not FDA-approved for any indication and is not a dietary supplement. It’s sold as a “research chemical” labeled not for human use. As of July 2026 it’s under review by the FDA’s Pharmacy Compounding Advisory Committee for the 503A compounding list, and the FDA’s own reviewers recommended against including it, though the committee votes separately from its staff.

What are the side effects of DSIP?

The small studies from the 1980s and 1990s reported good tolerability, with no sedation or hangover. That’s a limited signal from under 20 people per study, all intravenous. There’s no modern safety monitoring, no long-term data, and no testing of the subcutaneous route sold today. Because most DSIP is unregulated research-grade or compounded peptide, purity and sterility are additional unknowns.

DSIP vs melatonin: which has better evidence?

Melatonin has the more solid footing: it’s a hormone your body makes, with identified receptors and a replicated, if modest, evidence base, strongest for shifting sleep timing. DSIP has a set of small, mostly positive human sleep studies, but no identified receptor and no independent, adequately powered trial. Melatonin is proven-modest; DSIP is promising-unproven.

Can I take DSIP with my antidepressant or other psychiatric medication?

There’s no human data on DSIP combined with any psychiatric medication, so nobody can promise it’s safe. Its possible effects on the stress axis and enkephalin system are the kind of overlap that would matter clinically if they were better characterized, and they aren’t. If you’re on psychiatric medication, don’t add any peptide without your prescribing clinician’s involvement.

This article is for educational purposes only and is not medical advice. DSIP is not FDA-approved, is not offered or prescribed by this practice, and is discussed here only to explain what the evidence shows. Nothing here is a recommendation to use it. Talk with a qualified clinician about your own situation before making any treatment decision. If you’re in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. 1978;376(2):119-129. PMID: 568769
2. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PMID: 16539679
3. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345. PMID: 6895513
4. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129. PMID: 3622582
5. Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984;23(5):386-388. PMID: 6391926
6. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. PMID: 6689058
7. Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110. PMID: 3583493
8. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. PMID: 1299794
9. Nakamura A, Nakashima M, Sakai K, Niwa M, Nozaki M, Shiomi H. Delta-sleep-inducing peptide stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res. 1989;481(1):165-168. PMID: 2706459
10. Bjartell A, Ekman R, Bergquist S, Widerlöv E. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989;14(5):347-355. PMID: 2554357
11. Späth-Schwalbe E, Schäfer A, Uthgenannt D, Born J, Fehm HL. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995;20(3):231-237. PMID: 7777652
12. Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. 1983;10(4):205-208. PMID: 6328354
13. Backmund M, Meyer K, Rothenhäusler HB, Soyka M. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998;18(3):257-258. PMID: 9617990
14. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of DSIP in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385. PMID: 6548970
15. U.S. Food and Drug Administration. Emideltide (delta sleep-inducing peptide): FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026. FDA briefing document (PDF)
16. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA advisory committee calendar